Mycobacterium abscessus medical therapy: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 18: | Line 18: | ||
* Parenteral antibiotics: [[amikacin]] ''OR'' [[cefoxitin]] ''OR'' [[imipenem]] | * Parenteral antibiotics: [[amikacin]] ''OR'' [[cefoxitin]] ''OR'' [[imipenem]] | ||
===Antibiotic Dosage==== | ====Antibiotic Dosage==== | ||
===Pulmonary Infection=== | ===Pulmonary Infection=== | ||
Revision as of 19:41, 23 July 2014
|
Mycobacterium Abscessus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mycobacterium abscessus medical therapy On the Web |
|
American Roentgen Ray Society Images of Mycobacterium abscessus medical therapy |
|
Risk calculators and risk factors for Mycobacterium abscessus medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
Treatment
Skin and Soft Tissue Infections
The treatment of mycobacterium abscessus include the following:
- Draining collections of pus
- Surgical debridement[1]
- Administration of combination of antibiotics for a prolonged period of time: macrolide based regimen[1]
Antibiotic Regimen
In case of serious skin, soft tissues, and bones infection, a combination of antibiotics need to be administered:
PLUS
Antibiotic Dosage
Pulmonary Infection
- Administration of combination of antibiotics for a prolonged period of time: clarithromycin 1,000 mg/day based regimen[1]
- A combination of antibiotics is indicated for the treatment of pulmonary infection with mycobacterium abscessus; however, there is no evidence on the optimal multidrug regimen.
- Surgical resection of the localized disease[1]
- Surgical resection and multidrug antibiotic therapy is associated with a higher chance of a successful treatment.
References
- ↑ 1.0 1.1 1.2 1.3 Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F; et al. (2007). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". Am J Respir Crit Care Med. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. PMID 17277290.